Reason for request
Re-assessment of the Actual Benefit and Improvement in Actual Benefit in accordance with article R-163-21 of the Social Security Code.
Clinical Benefit
| Substantial |
The Actual Benefit of XEROQUEL LP in the treatment of schizophrenia is substantial. |
Clinical Added Value
| no clinical added value |
XEROQUEL LP does not provide an Improvement in Actual Benefit (IAB level V) compared with other treatments available in this indication. |
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
46RLj51xpP9Ba8ZS
Listen
